The FDA’s review of drug and biological products in this medication class is critical, as a brain impairment impacts between 6.5% and 7.9% of adults in the United States.
Scientists from the University of Eastern Finland have identified alterations occurring in the human brain that signal the early stages of this common neurogenerative disease.
Prescribing low-dose aspirin for preventing secondary cardiovascular disease is well established, but its safety and efficacy in primary prevention remains open to debate.